scholarly journals Rare Cause of Seizures, Renal Failure, and Gangrene in an 83-Year-Old Diabetic Male

2013 ◽  
Vol 2013 ◽  
pp. 1-5
Author(s):  
Stalin Viswanathan ◽  
Kandan Balamurugesan

We report an 83-year-old diabetic male who presented with acute-onset renal failure, seizures, psychosis, pneumonia, and right foot gangrene. Investigations revealed thrombocytopenia, CSF lymphocytosis, ANA and dsDNA positivity, hypocomplementemia, and pneumonitis following which he was treated with pulse methylprednisolone. He was treated forPseudomonas-related ventilator-associated pneumonia, candiduria, andE. coli-related bedsore infection prior to discharge. He was discharged at request and died 17 days later due to a respiratory infection.

2021 ◽  
Vol 10 (Supplement_1) ◽  
pp. S12-S12
Author(s):  
I Tinoco ◽  
A Jarrell ◽  
L Correa ◽  
J Bissler ◽  
J DeVincenzo ◽  
...  

Abstract Background Patients with deficiencies of terminal components of complement are at hundreds to thousands fold increased risk of severe and fatal Neisseria spp. infections compared with the general population. Eculizumab is a newly approved monoclonal antibody C5 complement inhibitor. It is indicated for the treatment of atypical hemolytic uremic syndrome (atypical HUS), myasthenia gravis, and paroxysmal nocturnal hemoglobinuria. Because of the complement-depleting effect of Eculizumab dosing (Soliris®, Alexion Pharmaceuticals, Munich, Germany), patients are immunosuppressed for specific infectious pathogens (including Neisseria species) against which protection partially relies on normal complement activity. Because Eculizumab treatment is associated with a dramatically increased risk of Neisseria species. infections, recommendations for Neisseria meningitidis vaccination and antibiotic prophylaxis are contained in Eculizumab prescribing information. However, the most appropriate prevention of infections after Eculizumab has yet to be determined. Methods Case report and literature review. Results A previously healthy 7-year-old male was diagnosed with atypical HUS which included renal failure progressing to dialysis, persistent thrombocytopenia, hemolytic anemia, and hemoglobinuria. Stool cultures and a stool multiplex PCR panel did not detect Shiga-like producing E. coli nor E. coli O157/H7. Eculizumab dosing was therefore planned and Infectious Diseases consultation was obtained for appropriate preventions. The FDA Prescribing Information recommends Neisseria meningitidis vaccination before starting Eculizumab or, if immediate Eculizumab is necessary, to use antibiotic prophylaxis until 2 weeks after vaccination. The accepted protective titer after meningococcal vaccination is population based and uses the serum bactericidal assay (SBA). An antibody titer of >1:4 (human compliment) or 1:8 (rabbit complement) is considered protective. However, this “gold standard” assay incorporates the use of exogenous human or rabbit complement. The protective SBA titers in subjects with terminal complement component deficiencies may not be properly assessed using these same SBA titer protective thresholds. Furthermore, serious meningococcal infections have occurred after appropriate vaccination in patients receiving chronic Eculizumab treatments (ie for paroxysmal nocturnal hemoglobinuria). Finally, SBA protective levels after single Neisseria meningitidis vaccination have not been achieved in majorities of patients with renal failure receiving dialysis and or transplant immunosuppression. Conclusions The current Eculizumab prescribing information recommendations for vaccination and antimicrobial prophylaxis may be inadequate to prevent serious Neisseria infections. Repeated Neisseria meningitidis vaccination and extended antibiotic prophylaxis may afford better protection in patients chronically dosed with Eculizumab.


2021 ◽  
Vol 13 (1) ◽  
pp. 161-170
Author(s):  
Jianyun Peng ◽  
Yongling Tao ◽  
Xiaoru Zhang ◽  
Meijuan Xiang ◽  
Zhihong Gui ◽  
...  

In order to purify blood and adsorb β2M, a highly selective immunosorbent biomaterial based on nano antibody was designed. First of all, nanoantibodies against β2M in patients with renal failure are screened by phage display library technology. After 4 rounds of screening, 12 kinds of monoclonal phage samples are compared by ELISA, and the highest affinity sequence A53 is obtained. Then, the nano antibody A53 is transferred into two kinds of host bacteria respectively, and the host E. coli Shuffle T7 is selected, and then purified by nickel column affinity, thus obtaining high purity nano antibody A53S. Five kinds of nano antibody adsorbents are prepared by using A53S as a component of adsorbent. The results show that the effect of D series adsorbent with ɛ-poly-L-lysine as spacer is better, but the ligand density should be adjusted reasonably to ensure the activity of nanoantibody protein. When the loading concentration of β2M is set to 1.8 mg/ml, adsorbent D-1 can adsorb 11.78 mg/ml of dynamic adsorption capacity of β2M. This index is significantly higher than the dynamic adsorption capacity of plasma system under the same conditions (P < 0.05), which proves that the nano antibody adsorbent biomaterial can effectively adsorb β2M, thus reducing the probability of dialysis complications.


Viruses ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 939
Author(s):  
Flávia Fonseca Bagno ◽  
Lara Carvalho Godói ◽  
Maria Marta Figueiredo ◽  
Sarah Aparecida Rodrigues Sérgio ◽  
Thaís de Fátima Silva Moraes ◽  
...  

Chikungunya virus (CHIKV) is a mosquito-borne pathogen that causes a disease characterized by the acute onset of fever accompanied by arthralgia and intense joint pain. Clinical similarities and cocirculation of this and other arboviruses in many tropical countries highlight the necessity for efficient and accessible diagnostic tools. CHIKV envelope proteins are highly conserved among alphaviruses and, particularly, the envelope 2 glycoprotein (CHIKV-E2) appears to be immunodominant and has a considerable serodiagnosis potential. Here, we investigate how glycosylation of CHIKV-E2 affects antigen/antibody interaction and how this affects the performance of CHIKV-E2-based Indirect ELISA tests. We compare two CHIKV-E2 recombinant antigens produced in different expression systems: prokaryotic-versus eukaryotic-made recombinant proteins. CHIKV-E2 antigens are expressed either in E. coli BL21(DE3)—a prokaryotic system unable to produce post-translational modifications—or in HEK-293T mammalian cells—a eukaryotic system able to add post-translational modifications, including glycosylation sites. Both prokaryotic and eukaryotic recombinant CHIKV-E2 react strongly to anti-CHIKV IgG antibodies, showing accuracy levels that are higher than 90%. However, the glycan-added viral antigen presents better sensitivity and specificity (85 and 98%) than the non-glycosylated antigen (81 and 71%, respectively) in anti-CHIKV IgM ELISA assays.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 859-859
Author(s):  
Qurana F. Lewis ◽  
Deirdra R. Terrell ◽  
Bernhard Lammle ◽  
Johanna Kremer-Hovinga ◽  
James N. George ◽  
...  

Abstract Diarrhea, often bloody diarrhea caused by infection with E. coli 0157:H7, is the prodrome for typical HUS in children. In adults, HUS has been reported following epidemics of enteric infections, however the frequency and clinical features of sporadic HUS or TTP in adults following a prodrome of bloody diarrhea have not been characterized. In the Oklahoma TTP-HUS Registry, January 1, 1989 to December 31, 2003, 19 (6%) of 301 consecutive patients had a prodrome of bloody diarrhea. The 19 cases were separated by time and location, indicating no common source outbreak. 5/10 patients who were appropriately tested had positive stool cultures for E. coli O157:H7. Although more cases (12/19, 63%) occurred in warm months, April–September, a seasonal difference was not significant (p= 0.25). We compared the clinical features of these 19 patients to the 119 patients who had no apparent etiologies or associated conditions and were therefore defined as idiopathic TTP-HUS. Bloody Diarrhea Idiopathic p-value (n=19) (n=119) Median values are presented for continuous data. Laboratory data: most abnormal value at diagnosis of TTP-HUS ± 7 days Age (years) 59 48 0.109 Race (% Black) 5% 25% 0.073 Gender (% female) 79% 74% 0.781 Obesity (BMI≥30 kg/m2) 21% 40% 0.120 Severe neurologic abnormalities 63% 49% 0.243 Platelet count 26 13 0.010 Hematocrit 22 22 0.931 LDH 1410 1305 0.115 Acute renal failure 68% 29% <0.001 Response to PE 84% 82% 1.000 ADAMTS13 deficiency (<5%) 0% (0/13) 30% (20/67) 0.031 Death 32% 19% 0.233 Relapse in 30 day survivors 0% 20% 0.119 Although women predominated in both groups, 18/19 patients with a prodrome of bloody diarrhea were White, consistent with the predominance of White subjects among children with diarrhea-associated HUS, but distinct from the significantly higher incidence of Blacks among adult patients with idiopathic TTP-HUS (compared to the incidence among other races, p<0.0001). 3 patients with a prodrome of bloody diarrhea never had an abnormal serum creatinine, therefore the term TTP-HUS, rather than HUS, may better describe these patients. The only significant differences in presenting features and outcomes were the severity of thrombocytopenia, the relative frequency of acute renal failure, and the relative frequency of severe ADAMTS13 deficiency (<5% activity). ADAMTS13 activity was measured in 13 of the 19 patients with a prodrome of bloody diarrhea (median 50%, range 5–100%). We conclude that there is a continuous occurrence of TTP-HUS in adults preceded by a prodrome of bloody diarrhea, presumably related to Shiga toxin-producing enteric infections, even in the absence of recognized outbreaks. Plasma exchange is an appropriate treatment for adult patients with a prodrome of bloody diarrhea since they cannot be accurately distinguished from patients with idiopathic TTP, they have a high mortality rate, and they apparently respond to plasma exchange treatment.


Bionatura ◽  
2021 ◽  
Vol 3 (3) ◽  
pp. 2022-2026
Author(s):  
Ekremah K. Shaker ◽  
Fatima A. Chaloob

A ureteral stent is most broadly used to manage upper urinary tract disorders such as obstruction and prevent post-endoscopic complications. However, the stent may become a niche for bacterial colonization. This study aimed to determine the rate of bacterial colonization and type of bacteria in internal ureteral stents and the risk factors associated with bacterial colonization. This prospective cross-sectional study included 100 consecutive adult patients who had temporary ureteral stenting as preparation for a secondary ureterorenoscopy at Al-Yarmook Hospital/ Baghdad. All included patients were negative for bacterial culture before stenting. Stent and urine culture were performed at the time of stent removal. The colonization rate and bacteriuria in patients with internal ureteral stent were 19% and 9%, respectively. The most common bacteria in-stent and urine were E. coli accounting for 31.58% and 33.33%. Pseudomonas aeruginosa was common in stent culture, representing 21.05%. Positive bacterial culture was confirmed in 19 stents and 9 urine samples. All cases with positive urine samples were also positive for culture. Thus, the sensitivity and specificity of urine culture for detection of stent colonization were 47.37% and 100%, respectively. Diabetes mellitus, chronic renal failure, and prolonged stenting were significantly associated with increased stent colonization. The ureteral stent could be a source of urinary tract infection. The most pathogenic bacteria associated with the ureter stent are E. coli and Pseudomonas aeruginosa. Risk factors associated with stent colonization are diabetes mellitus, chronic renal failure, and prolonged indwelling time.


2005 ◽  
Vol 10 (20) ◽  
Author(s):  
Kevin Pollock

Previous surveillance of childhood haemolytic uraemic syndrome (HUS) in Scotland has identified Escherichia coli O157 in over 90% of cases, and infection with E. coli O157 is now reported to be one of the major causes of acute renal failure in children


Urology ◽  
1981 ◽  
Vol 17 (1) ◽  
pp. 88-90 ◽  
Author(s):  
Floyd A. Katske ◽  
David A. Bloom ◽  
Andrei N. Lupu

Sign in / Sign up

Export Citation Format

Share Document